Thank You for posting the article about the CAR-T patient.
That article is EXACTLY why we held out so much hope for MRKR's Multi-TAA therapy. And also why we NEED MRKR's Multi-TAA to become successful.
Not so much "WE" the investors, but we, those patients who need it so much.
CAR-T, for all it's promises, has many flaws.
The main flaw, as expressed in the article, is that in order to get to the "CAR" part of it, the Chimeric Antigen Receptor part, the T cells HAVE TO BE genetically engineered.
Not easy, not quick, most hospitals have no means to do so, very expensive, and with many different genetically engineered therapies, whether CAR or RNAI or MRNA or CRISPR, many times the human body does not react well to genetically engineered products and the result is negative side effects that CAN and HAS killed patients, like cytokine release syndrome.
That is one of the MAJOR benefits of MRKR's Multi-TAA , it is NOT genetically engineered, can be done in days, at a MUCH LOWER cost, with NO cytokine release syndrome.
WE, the world, really needs a NOT genetically engineered therapy/potential cure.
For how many decades now have we tried "linker" technology, or "TIL" technology, or "kinase" technology, or "checkpoint" technology.
And YES, we have tried an "off the shelf" CAR-T product.
A CAR-T product that is NOT derived from the sick patients blood, but already made from random generic T cells.
Many years ago a French Company, Cellectis (CLLS) tried it and did not have much success that I could find.
ALSO, if you don't mind, may I please address the "dilutes their investors into oblivion" comment.
IF, in real life a company needs additional cash like Marker does, they have two choices.
#1, Do NOTHING, and therefore go out of business when cash runs out, and then everybody has NOTHING, ZERO.
#2, Dilute investors to raise cash so that they can continue operations and hopefully succeed in the future.
What would you prefer?
There is no magic solution, two options, option #1 of Do Nothing DOES lead to oblivion.
At least option #2 of Dilute holds out hope.
